Podcasts about Pediatric Research

Avec Dre Julie Autmizguine, pédiatre-infectiologue, et Stéphanie Tremblay, pharmacienne en pédiatrie générale et en maladies infectieuses, nous allons:définir l'ostéomyélite et l'arthrite septique (définition, physiopathologie, agents pathogènes, diagnostic, complications possibles);décrire les différentes options de traitements (chirurgical, médical);illustrer les notions abordées via des cas patients afin de répondre à des questions pratiques.Références:Société canadienne de pédiatrie. Le diagnostic et la prise en charge des infections ostéoarticulaires aiguës chez les enfants. 2018. Reconduit en janvier 2024. The Royal Children's Hospital Melbourne. Clinical Practice Guideline: Bone and joint infection. Mis à jour en 2021. Peltola H et al. Osteomyelitis-Septic Arthritis Study Group. Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. Pediatr Infect Dis J. 2010  Ballock RT et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop. 2009 Autmizguine J et al. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J. 2013Nielsen AB et al. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark. Lancet Child Adolesc Health. 2024 Alcobendas Rueda RM et al. Oral Versus Intravenous Antibiotics for Pediatric Osteoarticular Infection: When and to Whom? Pediatr Infect Dis J. 2022  Keren R et al. Pediatric Research in Inpatient Settings Network. Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children. JAMA Pediatr. 2015  AntibioPed. (2025) Messil inc. (Version 1.5.0) [Application mobile] Disponible sur l'AppStore et Google Play. Également disponible en version web.Captation et montage: Philippe Lacroix, spécialiste en audiovisuelIdée originale, réalisation et animation: Émilie Roy-St-PierreConseillères en communication: Katrine Louis-Seize et Pascale ChatagnierLogo: Équipe des communications et du graphisme du CHU Sainte-JustineMusique: Samuel Ross  Collègues, ami(e)s et famille, merci pour votre précieux soutien. © mgparkilo 2025Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

Send us a textThe quest for better outcomes in pediatric IBD has taken significant strides forward, and Dr. Jeremy Adler returns to Bowel Moments to guide us through the most promising research developments of the past year. Dr. Adler is a clinical Professor in the Division of Pediatric Gastroenterology at the University of Michigan and serves as the Interim Director of the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center. We discuss how medication dosing strategies have evolved dramatically, with compelling evidence showing that body surface area measurements work better than traditional weight-based dosing for younger children. This seemingly simple adjustment yields dramatically better results, particularly as children grow and develop through puberty. Regular therapeutic drug monitoring—checking medication levels every 6-12 months or more frequently during growth spurts—has also proven critical for maintaining disease control in the pediatric population.Prevention emerges as the cornerstone of Dr. Adler's research and clinical philosophy. The fascinating GEM study has identified changes in gut permeability that occur before IBD diagnosis, potentially opening doors to early intervention before symptoms appear. Meanwhile, Dr. Adler's own groundbreaking research demonstrates that early, aggressive treatment with anti-TNF medications can prevent serious complications like perianal fistulas, fistulas, and abscesses—complications that significantly impact quality of life and body image.We navigate the complex terrain of treatment barriers, from insurance denials to psychological resistance to "stronger" medications. Dr. Adler challenges common misconceptions, noting that injectable or infusion medications often have better safety profiles than some oral options that patients perceive as "less intense." The conversation turns to normalizing surgical options like ostomies when needed, with Dr. Adler advocating for early introduction to surgical teams—not because surgery is imminent, but because establishing relationships reduces trauma if intervention becomes necessary.With new medication mechanisms emerging and genetic markers helping to personalize treatment approaches, the research landscape offers real hope for children with IBD. Join us for this candid, informative discussion about protecting children from the worst outcomes of IBD through early intervention, personalized treatment, and collaborative care models that address both physical and mental wellbeing.Links: Research article- Preventing Fistulas and Strictures Among Children with Crohn's DiseaseJournal Article referenced- National Perspectives of Barriers by Insurance and Pharmacy Benefits Managers in Pediatric Inflammatory Bowel DiseaseImproveCareNowLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

We're thrilled to share a special episode drop from one of our producers, Kira Dineen, and her flagship podcast, DNA Today! As a multi award winning genetics podcast with over 12 years of groundbreaking episodes, DNA Today explores the latest in genetics and genomics through expert interviews and engaging discussions.    To celebrate the new year, this episode reflects back on the top genetics and genomics news stories during 2024. The top stories we chatted about are from the American Journal of Human Genetics' “Genomic medicine year in review: 2024” paper.    Joining Kira Dineen for this discussion are two leaders in genomics: Dr. Bruce Gelb and Dr. Eric Green. In this reflective conversation, Kira Dineen, Dr. Bruce Gelb, and Dr. Eric Green discusses the significant developments in genetics and genomics over the past year, including the recent American Society of Human Genetics (ASHG) conference. They explore themes such as variable expressivity, the integration of genomics in human genetics, and the importance of diversity in genomic research.    The discussion also highlights key publications in genomic medicine and the evolving landscape of genetic research, emphasizing the need for continued focus on prevention and the implications of polygenic risk scores. They converse about the evolving landscape of genomic medicine, highlighting key advancements in research, particularly in areas like hemochromatosis and CRISPR technology. They reflect on the rapid progress made in genomic sequencing, especially in newborns, and the transformative impact it has on healthcare, particularly in NICUs. The discussion emphasizes the importance of diverse studies and scalable solutions in genetic counseling, as well as the future potential of genomic medicine to save lives and improve health outcomes.    Top 2024 Genomic Medicine Advancements Testing and managing iron overload after genetic screening-identified hemochromatosis Actionable genotypes and their association with lifespan in Iceland Impact of digitally enhanced genetic results disclosure in diverse families Chronic disease polygenic risk scores for clinical implementation in diverse US populations Skeletal Muscle Ryanodine Receptor 1 Variants and Malignant Hyperthermia Treating inherited retinal disease with gene-editing Validation of a clinical breast cancer risk assessment tool for all ancestries Broader access to clinical genome sequencing benefits diverse individuals with rare diseases Benefits for children with suspected cancer from routine whole-genome sequencing Clinical signatures of genetic epilepsies precede diagnosis in electronic medical records   The Guests:    Bruce D. Gelb, M.D. is the Director and Gogel Family Professor of the Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai. He is Professor of Pediatrics and of Genetics and Genomic Sciences. Dr. Gelb completed a pediatric residency and pediatric cardiology fellowship at Babies Hospital of Columbia-Presbyterian Medical Center and Texas Children's Hospital at the Baylor College of Medicine, respectively. He joined the faculty at Mount Sinai in 1991 after fellowship and has remained there since. He developed and now oversees an extensive program in genomics/gene discovery for congenital heart disease. Dr. Gelb has received the E. Mead Johnson Award from the Society for Pediatric Research and the Norman J. Siegel New Member Outstanding Science Award from the American Pediatric Society. He was elected to the American Society of Clinical Investigation and the National Academy of Medicine (formerly, the Institute of Medicine). Dr. Gelb is the President for the American Pediatric Society, Immediate Past President for the International Pediatric Research Foundation and Treasurer-Elect for the American Society of Human Genetics. In addition to his research, he co-directs the Cardiovascular Genetics Program at Mount Sinai.   Dr. Eric Green is the director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH). As NHGRI director, Dr. Green leads the Institute's research programs and other initiatives. He has played an instrumental leadership role in developing many high-profile efforts relevant to genomics. Dr. Green received his B.S. degree in bacteriology from the University of Wisconsin - Madison in 1981, and his M.D. and Ph.D. degrees from Washington University in 1987. Coincidentally, 1987 was the same year that the word “genomics” was coined. Dr. Green's relationship with the Institute began long before his appointment as director. He served as the Institute's scientific director (2002 - 2009), chief of the NHGRI Genome Technology Branch (1996 - 2009) and founding director of the NIH Intramural Sequencing Center (1997 - 2009). Prior to that, he played an integral role in the Human Genome Project. Dr. Green is a founding editor of the journal Genome Research (1995 - present) and a series editor of Genome Analysis: A Laboratory Manual (1994 - 1998), both published by Cold Spring Harbor Laboratory Press. He is also co-editor of Annual Review of Genomics and Human Genetics (since 2005). Throughout his career, he has authored and co-authored over 385 scientific publications.    Dr. Green is a recurring guest on DNA Today, and he might hold the title as the guest who has been on the show the most times! He was featured on Episode #182 when we chatted about the Human Genome Project and the recent completion of the human genome sequence -- from telomere to telomere. Dr. Green was a panelist on the PhenoTips Speaker Series installment that our host Kira Dineen moderated about population genomics in clinical practice, this was also released on the DNA Today podcast feed as Episode #260. He was also on the last couple years for our genetics wrapped 2022 (#214) and 2023 (#263).    Be sure to subscribe to DNA Today wherever you get your podcasts to explore hundreds of episodes on topics ranging from genetic counseling to cutting-edge research in genomics. New episodes are released every Friday. In the meantime, you can binge over 300 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel, this includes some episodes recorded at NBC Universal Stamford Studios.    DNA Today is hosted and produced by Kira Dineen. Our video lead is Amanda Andreoli. Our social media lead is Kajal Patel. Our Outreach Intern is Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.    See what else we are up to on Instagram, X (Twitter), Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com. 

Avec Dr Jean-François Chicoine, pédiatre au CHU Sainte-Justine et professeur agrégé de clinique à l'Université de Montréal, ainsi que Pascal Bédard, pharmacien en pédiatrie générale au CHU Sainte-Justine, nous allons:explorer les options sans ordonnance pour le rhume et la grippe chez les enfants;discuter de la place du salicylate de bismuth, des probiotiques et de certains produits homéopathiques pour les problèmes gastrointestinaux;résumer quelles vitamines seraient appropriées et quels produits pour la douleur et le confort sont à privilégier.Merci beaucoup de prendre 2 minutes pour le sondage afin d'encourager le balado! Disponible ici ✨ (ouvert jusqu'au 19.01.2025)Références:CHU Sainte-Justine: ORL. L'hygiène nasale. 2024 et dépliant d'information: L'hygiène nasale.Smith SM et al. Over‐the‐counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database of Systematic Reviews 2014Paul IM et al. Effect of Honey, Dextromethorphan, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Children and Their Parents. Arch Pediatr Adolesc Med. 2007 Santé Canada. Norme d'étiquetage des médicaments pédiatriques en vente libre contre la toux et le rhume administrés par voie orale. 2009.Tang SC et al. Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatr Res. 2022 Green JL et al. Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics. 2017Goldman RD. Bismuth salicylate for diarrhea in children. Can Fam Physician. 2013Santé Canada. Information sur les produits homéopathiques et Preuves relatives aux médicaments homéopathiques. 2022National Center for Complementary and Integrative Health. Homeopathy: What You Need To Know. 2021Société canadienne de pédiatrie. La prévention de la carence en vitamine D symptomatique et du rachitisme chez les nourrissons et les enfants autochtones du Canada. 2022 Santé Canada. Aliments enrichis : Approche du Canada en matière d'enrichissement. 2024Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

As parents play key roles during childhood and adolescence, child-parent relationships, parenting styles and home environments have been identified as factors that may contribute to children's screen use patterns. Listen as the lead author/researcher, Dr. Jason Nagata, of an article titled, Associations Between Media Parenting Practices and Early Adolescent Screen Use published in a recent article in the Journal of  Pediatric Research, explains how parents' tech use can affect their kids' use of tech. It's very interesting and incredibly important. Listen today!  

This week Lu talks to special guest Dr Anna Cronin about the latest research and future directions in the care of children with cleft lip and palate. Find out more about Anna's work here: https://www.acu.edu.au/research-and-enterprise/our-people/anna-cronin Research we discuss: Cronin ,A. (2020). Toddlers with cleft palate: Enhancing communication through holistic child-and family-centred practice. Cronin, A., McLeod, S., & Verdon, S. (2020). Applying the ICF-CY to specialist speech-language pathologists' practice with toddlers with cleft palate speech. The Cleft Palate-Craniofacial Journal, 57(9), 1105-1116. Cronin, A., Verdon, S., & McLeod, S. (2021). Persistence, strength, isolation, and trauma: An ethnographic exploration of raising children with cleft palate. Journal of Communication Disorders, 91, 106102. Cronin, A., Verdon, S., & McLeod, S. (2020). Working with toddlers with cleft palate: Learning from clients and families. Journal of Clinical Practice in Speech-Language Pathology, 22(2), 101-110. Huang H-H, Hsu J-W, Huang K-L, et al. Congenital cleft lip and palate and elevated risks of major psychiatric disorders: A nationwide longitudinal study. Clinical Child Psychology and Psychiatry, 29(2), 637-647. https://doi.org/10.1177/1359104523120066 Junaid, M., Slack-Smith, L., Wong, K., Bourke, J., Baynam, G., Calache, H., & Leonard, H. (2022). Association between craniofacial anomalies, intellectual disability and autism spectrum disorder: Western Australian population-based study. Pediatric Research, 92(6), 1795-1804. https://doi.org/10.1038/s41390-022-02024-9 Tillman, K. K., Hakelius, M., Höijer, J., Ramklint, M., Ekselius, L., Nowinski, D., & Papadopoulos, F. C. (2018). Increased risk for neurodevelopmental disorders in children with orofacial clefts. Journal of the American Academy of Child & Adolescent Psychiatry, 57(11), 876-883. https://doi.org/10.1016/j.jaac.2018.06.024

Dr. Joel Warsh, also known as Dr. Gator, is a Board-Certified Pediatrician in Los Angeles specializing in Parenting, Wellness, and Integrative Medicine. Originally from Toronto, he earned degrees in Kinesiology, Psychology, and Epidemiology before completing his medical degree at Thomas Jefferson Medical College and his pediatric training at CHLA. He founded Integrative Pediatrics and Medicine Studio City in 2018. Dr. Warsh is a published researcher, media contributor, and founder of the Parenting Masterclass Platform, Raising Amazing. ___How Prepared is Your Team for the Next Big Disruption? Future-proof your team with Malosiminds.com Get your copy of Personal Socrates: Better Questions, Better Life Connect with Marc >>> Website | LinkedIn | Instagram | Twitter Drop a review and let me know what resonates with you about the show!Thanks as always for listening and have the best day yet!*A special thanks to MONOS, our official travel partner for Behind the Human! Use MONOSBTH10 at check-out for savings on your next purchase. ✈️*Special props

A family's access to specialty pediatric care can sometimes depend on their home address. Kristin Ray, MD, director of Health Systems Improvements with Children's Community Pediatrics (CCP), and a Mellon Scholar with the Richard King Mellon Foundation Institute for Pediatric Research, aims to improve the pediatric health care delivery system to make quality care more readily available to all. Dr. Ray discusses two interventions that can help with these challenges, telemedicine and electronic consultations, and the future of this specialty care delivery.

Bernhard Kühn, MD, is the director of research in Cardiology and an associate director for the Richard King Mellon Institute for Pediatric Research. The Kühn Lab focuses on cardiomyocytes and creating therapies that can help the heart muscle heal itself to recover from a heart attack or to help it restore a congenital heart defect to normal cardiac function without requiring surgery. He also reflects on the helpful collaboration with the cardiac surgery team here at UPMC Children's Hospital of Pittsburgh.

Can you name a disease where inflammation is not one of the major drivers? Scott Canna, MD, rheumatologist at UPMC Children's Hospital and a Mellon Scholar with the Richard King Mellon Foundation Institute for Pediatric Research, asks our hosts this question and talks about modulating our immune system in both rare and common diseases. Dr. Canna has been actively researching ways to better understand and treat inflammatory disorders for over a decade.

When George Gittes, MD, and his research team came across an outcome they weren't expecting, Dr. Gittes' surgical background helped identify an amazing discovery — using gene therapy to reverse autoimmune type I diabetes without immunosuppression. Hosts Stephanie Dewar, MD, and John Williams, MD, discuss the details of this fascinating study and more with Dr. Gittes. Dr. Gittes has recently been appointed the director of the Richard King Mellon Foundation Institute for Pediatric Research and co-scientific director at UPMC Children's Hospital of Pittsburgh.

When an infant is born, their first introduction is to a new immune system and new bacteria. Tim Hand, PhD, assistant professor with the Richard King Mellon Foundation Institute for Pediatric Research, takes samples from the neonatal intensive care unit (NICU) at UPMC Magee-Womens Hospital, to look at how antibodies in a mother's breast milk may shape the relationship between an infant and their microbiome. Listen in as Dr. Hand discusses the unique microbiome of premature infants, necrotizing enterocolitis (NEC), and how maternal IgA, an active component in a mother's breast milk, can shape a child's immune system.

Dr. Ann Anderson Berry is the Vice President of Research at Children's Nebraska and a professor and the executive director of the Child Health Research Institute. She serves as the UNMC John and Patti Sparks Chair of Pediatric Research, vice-chair of research in the Department of Pediatrics and the division chief of Neonatology. She is the founding medical director of the Nebraska Perinatal Quality Improvement Collaborative. Her research activities include funded federal and state research grants evaluating perinatal nutrition and the impact on maternal and fetal outcomes, and additional studies on Neonatal Opioid Withdrawal Syndrome, the impact of intrauterine opioid exposure on brain development, and the consequences of poor nutrition and social stressors on infants with intrauterine opioid exposure on neurodevelopment and long-term health. She is a constant advocate for Nebraska families and understands the importance of recognizing rural and urban needs when allocating perinatal resources. As a mentor to students at the undergraduate, medical student and resident and graduate level she works to prepare trainees to do impactful and outstanding work in their chosen fields. An Executive Leadership in Academic Medicine graduate, Dr. Anderson Berry serves on national committees for the American Society of Nutrition, the Pediatric Academic Society and Women in Neonatology. She completed her undergraduate studies at the University of Wyoming. She attended Creighton University for her medical degree. Her pediatric Residency and PhD were attained at the University of Nebraska Medical Center, and her fellowship was in Neonatology was completed at the University of Utah. She loves spending time with her husband and two daughters in the mountains of Wyoming.Some of the topics we discussed were:Dr. Berry's journey and experience in finding and providing mentorshipWhy having a mentor is importantWhere to start in finding a mentorHow to make sure that a mentorship is a two way street and is a mutually beneficial relationship for both the mentor and the menteeThe most effective ways of learning when you are receiving mentorship and being the best mentee you can beThe most effective ways of teaching when you are giving mentorship and being the best mentor you can beWhat some of the most common styles of mentorship are How to approach ending a mentorship from the perspective of both a mentor and a mentee without making the other person feel uncomfortableWhat lessons Dr. Berry has learned and what mistakes to avoid3 tips for physicians who are at the beginning of their career that are looking for a mentor or for experienced physicians who are interested in mentoring someoneAnd more!Learn more about me or schedule a FREE coaching call:https://www.joyfulsuccessliving.com/Join the Voices of Women Physicians Facebook Group:https://www.facebook.com/groups/190596326343825/Connect with Dr. Berry:Website:https://www.childrensnebraska.org/provider/ann-l-anderson-berry-m-d/Email:aberry@childrensnebraska.orgTwitter:@aandersonberry

In this episode of “At the Bench”, we are interviewing one of our show's co-hosts, Dr. David McCulley. David is a neonatologist and developmental biologist at the University of California, San Diego and in this show he talks about what motivated him to build a research program investigating the genetic and developmental mechanisms responsible for congenital diaphragmatic hernia (CDH). David directs an NIH-supported study to determine the genetic mechanisms responsible for abnormal lung and pulmonary vascular development in patients with CDH. He describes the mentorship and collaborative research experiences that have shaped his career path. David also talks about the work that he is doing along with the Society for Pediatric Research and the co-hosts of this program, Dr. Misty Good and Dr. Betsy Crouch, to encourage and promote pediatric physician-scientist career development. Some highlighted papers: Stokes, G., Li, Z., Talaba, N., Genthe, W., Brix, M.B., Pham, B., Wienhold, M.D., Sandok, G., Hernan, R., Wynn, J., Tang, H., Tabima, D.M., Rodgers, A., Hacker, T.A., Chesler, N.C., Zhang, P., Murad, R., Yuan, J.X., Shen, Y., Chung, W.K., McCulley, D.J. Rescuing lung development through embryonic inhibition of histone acetylation. Science Translational Medicine. 2024 Jan 31;16(732). Epub 2024 Jan 31. https://pubmed.ncbi.nlm.nih.gov/38295182/Qiao, L., Wynn, J., Yu, L., Hernan, R., Zhou, X., Duron, V., Aspelund, G., Farkouh-Karoleski, C., Zygumunt, A., Krishnan, U.S., Nees, S., Khlevner, J., Lim, F.Y., Crombleholme, T., Cusick, R., Azarow, K., Danko, M.E., Chung, D., Warner, B.W., Mychaliska, G.B., Potoka, D., Wagner, A.J., Soffer, S., Schindel, D., McCulley, D.J., Shen, Y., Chung, W.K. Likely damaging de novo variants in congenital diaphragmatic hernia patients are associated with worse clinical outcomes. Genetics in Medicine. 2020 Dec;22(12):2020-2028. https://pubmed.ncbi.nlm.nih.gov/32719394/McCulley, D.J., Wienhold, M.D., Hines, E.A., Hacker, T.A., Rogers, A., Pewowaruk, R.J., Zewdu, R. Chesler, N.C., Selleri, L., Sun, X. PBX transcription factors drive pulmonary vascular adaptation to birth. Journal of Clinical Investigation. 2018 Feb 1;128(2):655-667. https://pubmed.ncbi.nlm.nih.gov/29251627/Kardon, G., Ackerman, K., McCulley, D.J., Shen, Y., Wynn, J., Shang, L., Bogenschutz, E.L., Sun, X., Chung, W.K. Congenital diaphragmatic hernias: from genes to mechanisms to therapies. Disease Models & Mechanisms. 2017 Aug 1;10(8):955-970. https://pubmed.ncbi.nlm.nih.gov/28768736/McCulley, D., Wienhold, M.D., Sun, X. “The pulmonary mesenchyme directs lung development.” Current Opinion in Genetics & Development. 2015 Jun;32:98-105. https://pubmed.ncbi.nlm.nih.gov/25796078/As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

The United Nations recently stated that “climate change is the defining issue of our time, and we are at a defining moment” (https://www.un.org/en/global-issues/climate-change). This statement ended the political debate about the role of human activities in climate change. Global climate change is happening and it will have a profound effect on our children.Listen and learn from Dr. Kari Nadeau the Chair of Environmental Health from Harvard School of Public Health and one of the guest editors of Pediatric Research's special issue on climate change. Read Dr. Nadeau's editorial here: Global climate change: the defining issue of our time for our children's health | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Illness severity scores are commonly used for mortality prediction and risk stratification in pediatric critical care research. However, as mortality has steadily declined in the pediatric intensive care unit there has been increasing attention given to evaluating non-mortality outcomes in survivors. In this episode we meet Early Career Investigator Elizabeth Killien from Seattle Children's Hospital. In order to evaluate the ability of two commonly used illness severity scores to predict morbidity outcomes, she performed a secondary analysis of the Life After Pediatric Sepsis Evaluation (LAPSE) multicenter longitudinal cohort study of functional and health-related quality of life outcomes among survivors of septic shock.Read the full article here: Predicting functional and quality-of-life outcomes following pediatric sepsis: performance of PRISM-III and PELOD-2 | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Hypoxic Ischaemic Encephalopathy (HIE), a subset of neonatal encephalopathy, is the most common neurological condition in term born infants. It is known that a range of acute and chronic placental pathologies are more common in infants with HIE. However little is known about how differences in utero-placental function might contribute to varied outcomes in these infants.In this episode of Pediapod, we speak to Early Career Investigator Dr. Jeffrey Russ from Duke University Medical Center, who retrospectively analyzed whether acute versus chronic placental pathology were differentially associated with outcomes in patients with presumed HIE.Read the full study here: The association of placental pathology and neurodevelopmental outcomes in patients with neonatal encephalopathy | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

The development of children born very preterm is most often evaluated using the Bayley Scales of Infant Development. These single assessments are routinely used as outcome measures for neonatal interventions or as a means of prognosis. However, early Bayley scores may not accurately predict later outcomes. In this episode of Pediapod, we speak to Dr. Mary Lauren Neel from Emory University who, along with her team, set up a study to determine whether Bayley-III score trajectories measured at multiple timepoints in children born very preterm, predicted school readiness at age 5, better than a single assessment. Read the full study here: Bayley trajectories predict school readiness better than single assessments in formerly very preterm preschoolers | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

In this episode Elizabeth Barnert, MD, MPH, FAAP, explains why the AAP advocates for reform of the juvenile justice system. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Tamara D. Simon, MD, MSPH, FAAP, about increasing diversity in the pediatric research workforce. For resources go to aap.org/podcast.

A 1978 UMKC School of Medicine graduate, Dr. Jackson completed a pediatric residency at Cincinnati Children's and an infectious diseases fellowship at the University of Texas Southwestern before joining Children's Mercy Kansas City faculty in 1984. Acknowledged locally, regionally, and nationally as an educator on pediatrics and pediatric infectious diseases topics, she is recognized for developing one of the most robust pediatric infectious diseases programs in the country and for educating thousands of students, residents, fellows, and faculty in pediatrics throughout her nearly 40-year career. In 2019, she was recognized with the American Academy of Pediatrics award for Lifetime Contribution to Infectious Diseases Education. A fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Pediatric Infectious Disease Society, she served as a National Vaccine Advisory Committee member from 2017-2021. She has also been elected to the Alpha Omega Alpha Honor Society, the American Pediatric Society, the Society of Pediatric Research, and the Academic Pediatric Association.  She is a national thought leader in pediatric infectious disease topics. In 2014 with her colleagues at Children's Mercy, she identified the first cases of enterovirus D68 infection, leading to a CDC investigation that alerted pediatric providers around the country to the largest outbreak ever of this unique virus that led to respiratory failure and a polio-like syndrome that followed infection. Her research efforts have focused on the characterization of Kawasaki disease, prevention of antibiotic resistance, judicious use of antibiotics, emerging viruses, and optimal use of vaccines. During the COVID-19 pandemic, she has served on University, state, and national advisory committees. For the last five years, Dr. Jackson has been the Dean of the UMKC School of Medicine, working to promote recruitment and retention of a diverse student body and faculty, inspire changes in an already innovative curriculum, and promote a vibrant discovery enterprise for their MD degree programs, the Masters in Science Physician Assistant, the Masters in Science Anesthesia Assistant and Graduate Health Education programs.This show was made possible by a generous corporate contribution from PBG. Physician Buying Group, helping pediatricians vaccinate children. Support the showPlease subscribe to our podcast on Apple or Amazon and give us a 5-star review. The Pediatric Lounge - A Podcast taking you behind the door of the Physician's Lounge to get a deeper insight into what docs are talking about today, from the clinically profound to the wonderfully routine...and everything in between. The conversations are not intended as medical advice, and the opinions expressed are solely those of the host and guest.

A 1978 UMKC School of Medicine graduate, Dr. Jackson completed a pediatric residency at Cincinnati Children's and an infectious diseases fellowship at the University of Texas Southwestern before joining Children's Mercy Kansas City faculty in 1984. Acknowledged locally, regionally, and nationally as an educator on pediatrics and pediatric infectious diseases topics, she is recognized for developing one of the most robust pediatric infectious diseases programs in the country and for educating thousands of students, residents, fellows, and faculty in pediatrics throughout her nearly 40-year career. In 2019, she was recognized with the American Academy of Pediatrics award for Lifetime Contribution to Infectious Diseases Education. A fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Pediatric Infectious Disease Society, she served as a National Vaccine Advisory Committee member from 2017-2021. She has also been elected to the Alpha Omega Alpha Honor Society, the American Pediatric Society, the Society of Pediatric Research, and the Academic Pediatric Association.  She is a national thought leader in pediatric infectious disease topics. In 2014 with her colleagues at Children's Mercy, she identified the first cases of enterovirus D68 infection, leading to a CDC investigation that alerted pediatric providers around the country to the largest outbreak ever of this unique virus that led to respiratory failure and a polio-like syndrome that followed infection. Her research efforts have focused on the characterization of Kawasaki disease, prevention of antibiotic resistance, judicious use of antibiotics, emerging viruses, and optimal use of vaccines. During the COVID-19 pandemic, she has served on University, state, and national advisory committees. For the last five years, Dr. Jackson has been the Dean of the UMKC School of Medicine, working to promote recruitment and retention of a diverse student body and faculty, inspire changes in an already innovative curriculum, and promote a vibrant discovery enterprise for their MD degree programs, the Masters in Science Physician Assistant, the Masters in Science Anesthesia Assistant and Graduate Health Education programs.This show was made possible by a generous corporate contribution from Canid.  They do everything: from buying the vaccines, to managing all the paperwork, to making sure you get paid fairly for both private and VFC vaccines. You simply scan the vaccine and you're done!We partnered with them to offer you a free lunch where they'll help you understand the financials of your vaccine program in more depth. Just go to: Canid.io/lounge to learn more. Support the showPlease subscribe to our podcast on Apple or Amazon and give us a 5-star review. The Pediatric Lounge - A Podcast taking you behind the door of the Physician's Lounge to get a deeper insight into what docs are talking about today, from the clinically profound to the wonderfully routine...and everything in between. The conversations are not intended as medical advice, and the opinions expressed are solely those of the host and guest.

Pediatrics Now Host and Producer Holly Wayment interviews Dr. Mary Anne Jackson. A 1978 graduate of the UMKC School of Medicine, Dr. Mary Anne Jackson completed pediatric residency at Cincinnati Children's, and infectious diseases fellowship at the University of Texas Southwestern, before joining the faculty at Children's Mercy Kansas City in 1984. She has served as the Dean of the University of Missouri School of Medicine since 2018. Acknowledged locally, regionally, and nationally as an astute clinician and educator on pediatrics and pediatric infectious diseases topics, she is recognized for developing one of the most robust pediatric infectious diseases programs in the country and for educating thousands of students, residents, fellows, and faculty in pediatrics throughout her nearly 40-year career. In 2019, she was recognized with the American Academy of Pediatrics award for Lifetime Contribution in Infectious Diseases Education. A fellow of the American Academy of Pediatrics, the Infectious Disease Society of America, and the Pediatric Infectious Disease Society, she served as a member of the National Vaccine Advisory Committee from 2017-2021. She has also been elected to Alpha Omega Alpha Honor Society, the American Pediatric Society, the Society of Pediatric Research, and the Academic Pediatric Association.  She is a national thought leader in pediatric infectious disease topics and in 2014 with her colleagues at Children's Mercy, she identified the first cases of enterovirus D68 infection, leading to a CDC investigation that alerted pediatric providers around the country to the largest outbreak ever of this unique virus that led to respiratory failure and a post infection polio like syndrome in some children. Her research efforts have focused on characterization of Kawasaki disease, prevention of antibiotic resistance, judicious use of antibiotics, emerging viruses, and optimal use of vaccines. During the COVID-19 pandemic, she has served on advisory committees at the University, the state and national level.

Bronchopulmonary dysplasia (BPD) is the most common morbidity among very preterm infants. Commonly, nutritional interventions are focused on achieving optimal body weight gain. However, very preterm infants with evolving lung disease often experience disproportionate growth in the neonatal period, which may contribute to the odds of developing BPD.In this episode of Pediapod, we speak to Early Career Investigator Marc Beltempo from McGill University, Montréal, Canada who has investigated the link between change in body mass index and evolving BPD in very preterm infants.Read the full study here: The association between BMI trajectories and bronchopulmonary dysplasia among very preterm infants | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Kawasaki disease is a common childhood vasculitis and its global incidence appears to be increasing. Although this disease is self-limiting, the associated vasculopathy can cause cardiovascular complications.In this episode of Pediapod, we meet Early Career Investigator Cal Robinson at the Hospital for Sick Children, Toronto, Canada who performed a population-based cohort study using Ontario health administrative databases to determine the risk of cardiovascular events and mortality after Kawasaki disease.Read the full study here: Cardiovascular outcomes in children with Kawasaki disease: a population-based cohort study | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Today's guest is a sports medicine physician who has 41 peer-reviewed articles to his credit. He has been the team physician at Brown University since 2012, and is an active member of the Pediatric Research and Sports Medicine Society. Please welcome to the show, Dr. Peter KrizPRODUCED BY:Lagos Creative

Digging into pediatric research for children with rare, undiagnosed diseases Dr. Stuart Turvey, Canada Research Chair in Pediatric Precision Health and Lead of the Precision Health Initiative Learn more about your ad choices. Visit megaphone.fm/adchoices

Neonatal opioid withdrawal syndrome (NOWS) represents a major public health problem in the US with a high socioeconomic burden. The pathophysiology of this condition is not yet fully understood. Data from animal models have shown that opioids modulate brain reward signalling via an inflammatory cascade, however no such data exist for opioid-exposed neonates.In this episode of Pediapod we meet Early Career Investigator Elizabeth Yen, an assistant professor of pediatrics at Tufts University School of Medicine. She recently published a pilot study which looked at the effects of prenatal opioid exposure on gene expression and white matter injury. Read the full study here: Sex-specific inflammatory and white matter effects of prenatal opioid exposure: a pilot study | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Rare diseases affect millions of people in the USA. However, access to subspecialty care is not distributed equitably and there may be other barriers to clinic attendance. Furthermore, once established within the genetics clinic, families may still face barriers along the path to getting a molecular diagnosis.In this episode, we meet Early Career Investigator, Monica Wojcik, a neonatologist and geneticist at Boston Children's Hospital who ran a study to determine the influence of social determinants of health on the care-cascade following referral to a high-volume pediatric outpatient genetics clinic. Read the full study here: Rare diseases, common barriers: disparities in pediatric clinical genetics outcomes | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Systemic lupus erythematosus (SLE) causes significant long-term morbidity and mortality, particularly in children. There is some evidence that the innate immune system, in particular neutrophil activity, can be compromised in adult-onset lupus. Yet there is a paucity of data on neutrophil activity in pediatric SLE. This month on Pediapod, we join Early Career Investigator, Rakesh Kumar Pilania, an assistant professor at the postgraduate Institute of Medical Education and Research in Chandigarh, India to discuss his study of neutrophil activity in patients with pediatric SLE and what it reveals about the etiology of this condition.Read the full study here. Pediatric systemic lupus erythematosus: phagocytic defect and oxidase activity of neutrophils | Pediatric Research (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Over the past year, several INNOVATORS were devoted to learning more about the state of pediatric research. In this podcast, we learn about a breakthrough in the development of tissue from silk for use in the treatment of children born with spinal bifida.  Dr. Carlos Estrada holds appointments at Boston Children's Hospital and Harvard Medical School and was instrumental in the development and use of a new type of tissue. He earned his undergraduate degree from College of the Holy Cross and the MD from Wright State University Boonshoft School of Medicine. He completed an internship and residencies at Rush University Medical Center, then accepted a fellowship at Boston Children's Hospital from which he accepted an appointment to the faculty there. He earned an MBA from MIT. He focuses his research on tissue engineering and neurogenic bladder dysfunction. In today's podcast, he responds to the following questions: Describe the work you and your colleagues have been engaged in, particularly the rationale for pursuing it as well as its significance for the treatment of children?  Since launching INNOVATORS nearly 5 years ago, we've encountered several instances in a variety of fields including veterinary medicine and prosthetics, to mention only two, where the search for material that might be a substitute for surface skin was the “holy grail”. Your work seems to open up a much broader spectrum of applications. What are some of those and are the applications direct and straightforward or do they entail more research?  The announcement of your breakthrough was attended by an emphasis on the importance of collaboration that transcended areas of specialization and perhaps even entire fields. Who/what were those other partners and how did the collaboration come about and how was it sustained? Specifically, what role did leadership, on the part of an individual or a group of decision makers, play in facilitating collaboration?  The kind of research you and colleagues have been involved with requires resources. What kinds and which sources of resources were instrumental in advancing your research? Finally, even as you revel in what your research has accomplished, do you look out beyond the more immediate uses of your findings to applications that have become a bit more feasible precisely because of what the research makes possible now? What are some of those? INNOVATORS is a podcast production of Harris Search Associates.  *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*

Identify rare pediatric priority review vouchers.Recite the RACE for Children Act and Give Kids a Chance Act reforms of the Pediatric Cancer Research Equity Act.Describe pediatric exclusivity.Discuss the relaxed age eligibility requirements for adult cancer studies.Explain the requirements and opportunities of the following regulatory science policies to access novel therapies and funds for pediatric translational research

Dr. Ravi Mangal Patel is an Associate Professor of Pediatrics and Director of Neonatal Clinical Research at Emory University and Children's Healthcare of Atlanta. He is passionate about evidence-based medicine. His research interests include necrotizing enterocolitis, neonatal transfusion, caffeine therapy and perinatal epidemiology.  He is an executive committee member of the American Academy of Pediatrics, Section on Neonatal-Perinatal Medicine. He is also a principal investigator in the NICHD Neonatal Research Network, chair of the International Society for Evidence-Based Neonatology (EBNEO) and president of the Southern Society for Pediatric Research.Dr. Patel received his MD from the Medical College of Georgia and an MSc from Emory University.Find out more about Ravi and this episode at: www.the-incubator.org/086-dr-ravi-m-patel-md/______________________________________________________________________________________As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. enjoy!This podcast is proudly sponsored by Chiesi. 

For depressed preterm neonates, initiating positive pressure ventilation is the most important factor in facilitating transition. Therefore the recommendation for depressed neonates is to immediately cut the umbilical cord and begin resuscitation. However, many studies have shown that delaying the clamping of the umbilical cord also benefits preterm infants by increasing a neonate's blood volume, oxygenation and circulatory stabilisation, thus aiding transition. In this episode, we meet Early Career Investigator, Praveen Chandrasekharan from the State University of New York. He has used an asphyxiated preterm ovine model to ascertain the best practice of placental transfusion in a depressed neonate requiring resuscitation. Read the full article here. Placental transfusion during neonatal resuscitation in an asphyxiated preterm model | Pediatric Research (nature.com) Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

In the fiscal year 2021, the National Institute of Health (NIH) funded only 16,959 out of 80,878 research project grants.  In other words, the success rate was 21%. And the total funding amount was $8,827,444,624. The question I had was, “What does it take to get grant approval and launch an NIH funded research project?” To answer this question, I invited Dr. Manish Shah,  Professor of Pediatrics at Baylor College of Medicine and Attending Physician in the Texas Children's Hospital Emergency Center in Houston.  Dr. Shah has served on several national committees to advocate for improvements in pediatric and prehospital emergency care.  His research has focused on developing, implementing, and studying outcomes related to evidence-based protocols for various clinical conditions, including seizures.  Dr. Shah is currently the Principal Investigator for the Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study, which has been funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is being conducted in the Pediatric Emergency Care Applied Research Network (PECARN). Please join me in welcoming Dr. Shah on the Clinical Trial Podcast.  This episode is brought you by Florence Healthcare. To learn more, please visit https://florencehc.com/

Ask the Chiropractor- I was asked about a few different questions on Chiropractors role in regards to pediatric findings.  Children seem to have different health concerns as they age.  Has having a child under chiropractic care been beneficial in helping and preventing different alignments?  #healthy815 www.rockforddc.com

Ask the Chiropractor- I was asked about a few different questions on Chiropractors role in regards to pediatric findings.  Children seem to have different health concerns as they age.  Has having a child under chiropractic care been beneficial in helping and preventing different alignments?  #healthy815 www.rockforddc.com

Dr Jayasree Nair is a Clinical Associate Professor of Pediatrics and Program director of the Neonatal Perinatal Fellowship program at the University of Buffalo, and attending neonatologist at John R Oishei Hospital, Buffalo.After medical training and Pediatric residency in India, she completed her second pediatric residency and neonatology fellowship at the University at Buffalo. She then joined the Department of Pediatrics as a “Buswell” research faculty studying the effect of transfusions on mesenteric blood flow and reactivity. She is a physician scholar and educator combining her passion for improving clinical care, education and mentoring pediatric and neonatal trainees while continuing her research interests- in neonatal resuscitation and necrotizing enterocolitis. For her translational research on neonatal resuscitation, she has received grants from the American Academy of Pediatrics and the NIH-NICHD. She is involved in regional and national pediatric organizations, currently including the roles of Chair, Planning Committee for the Eastern Society of Pediatric Research and Chair- Student, Resident and House Officer Awards Selection Committee at the Society for Pediatric Research annual conference. Find out more about Jayasree and this episode at: www.the-incubator.org/064-jayasree-nair-md/______________________________________________________________________________________As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. enjoy!This podcast is proudly sponsored by Chiesi.

Episode Notes:TTN vs RDSNeonatal Resources, the Podcast Listen to Michelle and Darla compare and contrast transient tachypnea of the newborn with respiratory distress syndrome. They talk about:Risk factorsWho is most likely to be impactedThe importance of developmental careClinical managementThere is quite a bit of surfactant discussion, and to be fair, surfactant is often a huge component of NICU management. Check out the Get Your Pens blog To Surf or Not to Surf (if you don't see a hyperlink, check back, it's still in process) for a deep dive into methods of surfactant administration, what makes artificial surfactants work, and how the types of surfactant differ.For visual folks and side by side comparison…Get Your Pens.References:Amitai Komem, D., Meyer, R., Yinon, Y., & Levin, G. (2021). Prediction of meconium aspiration syndrome by data available before delivery. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14034 Alhassen, Z., Vali, P., Guglani, L., Lakshminrusimha, S., & Ryan, R. M. (2021). Recent Advances in Pathophysiology and Management of Transient Tachypnea of Newborn. Journal of Perinatology, 41(1), 6–16. https://doi.org/10.1038/s41372-020-0757-3Bonk, M. P., & Reilly, J. P. (2019). Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society, 16(2), 197–199. https://doi.org/10.1513/AnnalsATS.201810-697EDGomella, T. L., Eyal, F. G., & Bany-Mohammed, F. (2020). Neonatology; Management, Procedures, on-call problems, diseases, and drugs. (8th Ed).  McGraw Hill Lange. Chapter 106Jnah, A. J., & Trembath, A. N. (2019). Fetal and neonatal physiology for the advanced practice nurse. Springer Publishing Company. Chapter 4Jobe, A. H. (2019). Why, when, and how to give surfactant. Pediatric Research, 86(1), 15–16. https://doi.org/10.1038/s41390-019-0372-1Ng, E. H., & Shah, V. (2021). Guidelines for surfactant replacement therapy in neonates. Paediatrics & child health, 26(1), 35–49. https://doi.org/10.1093/pch/pxaa116Razak, A. (2022). Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. JAMA: Journal of the American Medical Association, 327(16), 1613. https://doi.org/10.1001/jama.2022.2923For definitions of the terms we used, check out the full episode page at TTN vs RDS

Episode Notes:TTN vs RDSNeonatal Resources, the Podcast Listen to Michelle and Darla compare and contrast transient tachypnea of the newborn with respiratory distress syndrome. They talk about:Risk factorsWho is most likely to be impactedThe importance of developmental careClinical managementThere is quite a bit of surfactant discussion, and to be fair, surfactant is often a huge component of NICU management. Check out the Get Your Pens blog To Surf or Not to Surf (if you don't see a hyperlink, check back, it's still in process) for a deep dive into methods of surfactant administration, what makes artificial surfactants work, and how the types of surfactant differ.For visual folks and side by side comparison…Get Your Pens.References:Amitai Komem, D., Meyer, R., Yinon, Y., & Levin, G. (2021). Prediction of meconium aspiration syndrome by data available before delivery. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14034 Alhassen, Z., Vali, P., Guglani, L., Lakshminrusimha, S., & Ryan, R. M. (2021). Recent Advances in Pathophysiology and Management of Transient Tachypnea of Newborn. Journal of Perinatology, 41(1), 6–16. https://doi.org/10.1038/s41372-020-0757-3Bonk, M. P., & Reilly, J. P. (2019). Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society, 16(2), 197–199. https://doi.org/10.1513/AnnalsATS.201810-697EDGomella, T. L., Eyal, F. G., & Bany-Mohammed, F. (2020). Neonatology; Management, Procedures, on-call problems, diseases, and drugs. (8th Ed).  McGraw Hill Lange. Chapter 106Jnah, A. J., & Trembath, A. N. (2019). Fetal and neonatal physiology for the advanced practice nurse. Springer Publishing Company. Chapter 4Jobe, A. H. (2019). Why, when, and how to give surfactant. Pediatric Research, 86(1), 15–16. https://doi.org/10.1038/s41390-019-0372-1Ng, E. H., & Shah, V. (2021). Guidelines for surfactant replacement therapy in neonates. Paediatrics & child health, 26(1), 35–49. https://doi.org/10.1093/pch/pxaa116Razak, A. (2022). Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. JAMA: Journal of the American Medical Association, 327(16), 1613. https://doi.org/10.1001/jama.2022.2923For definitions of the terms we used, check out the full episode page at TTN vs RDS

Episode Notes:TTN vs RDSNeonatal Resources, the Podcast Listen to Michelle and Darla compare and contrast transient tachypnea of the newborn with respiratory distress syndrome. They talk about:Risk factorsWho is most likely to be impactedThe importance of developmental careClinical managementThere is quite a bit of surfactant discussion, and to be fair, surfactant is often a huge component of NICU management. Check out the Get Your Pens blog To Surf or Not to Surf (if you don't see a hyperlink, check back, it's still in process) for a deep dive into methods of surfactant administration, what makes artificial surfactants work, and how the types of surfactant differ.For visual folks and side by side comparison…Get Your Pens.References:Amitai Komem, D., Meyer, R., Yinon, Y., & Levin, G. (2021). Prediction of meconium aspiration syndrome by data available before delivery. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14034 Alhassen, Z., Vali, P., Guglani, L., Lakshminrusimha, S., & Ryan, R. M. (2021). Recent Advances in Pathophysiology and Management of Transient Tachypnea of Newborn. Journal of Perinatology, 41(1), 6–16. https://doi.org/10.1038/s41372-020-0757-3Bonk, M. P., & Reilly, J. P. (2019). Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society, 16(2), 197–199. https://doi.org/10.1513/AnnalsATS.201810-697EDGomella, T. L., Eyal, F. G., & Bany-Mohammed, F. (2020). Neonatology; Management, Procedures, on-call problems, diseases, and drugs. (8th Ed).  McGraw Hill Lange. Chapter 106Jnah, A. J., & Trembath, A. N. (2019). Fetal and neonatal physiology for the advanced practice nurse. Springer Publishing Company. Chapter 4Jobe, A. H. (2019). Why, when, and how to give surfactant. Pediatric Research, 86(1), 15–16. https://doi.org/10.1038/s41390-019-0372-1Ng, E. H., & Shah, V. (2021). Guidelines for surfactant replacement therapy in neonates. Paediatrics & child health, 26(1), 35–49. https://doi.org/10.1093/pch/pxaa116Razak, A. (2022). Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. JAMA: Journal of the American Medical Association, 327(16), 1613. https://doi.org/10.1001/jama.2022.2923For definitions of the terms we used, check out the full episode page at TTN vs RDS

Episode Notes:TTN vs RDSNeonatal Resources, the Podcast Listen to Michelle and Darla compare and contrast transient tachypnea of the newborn with respiratory distress syndrome. They talk about:Risk factorsWho is most likely to be impactedThe importance of developmental careClinical managementThere is quite a bit of surfactant discussion, and to be fair, surfactant is often a huge component of NICU management. Check out the Get Your Pens blog To Surf or Not to Surf (if you don't see a hyperlink, check back, it's still in process) for a deep dive into methods of surfactant administration, what makes artificial surfactants work, and how the types of surfactant differ.For visual folks and side by side comparison…Get Your Pens.References:Amitai Komem, D., Meyer, R., Yinon, Y., & Levin, G. (2021). Prediction of meconium aspiration syndrome by data available before delivery. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14034 Alhassen, Z., Vali, P., Guglani, L., Lakshminrusimha, S., & Ryan, R. M. (2021). Recent Advances in Pathophysiology and Management of Transient Tachypnea of Newborn. Journal of Perinatology, 41(1), 6–16. https://doi.org/10.1038/s41372-020-0757-3Bonk, M. P., & Reilly, J. P. (2019). Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society, 16(2), 197–199. https://doi.org/10.1513/AnnalsATS.201810-697EDGomella, T. L., Eyal, F. G., & Bany-Mohammed, F. (2020). Neonatology; Management, Procedures, on-call problems, diseases, and drugs. (8th Ed).  McGraw Hill Lange. Chapter 106Jnah, A. J., & Trembath, A. N. (2019). Fetal and neonatal physiology for the advanced practice nurse. Springer Publishing Company. Chapter 4Jobe, A. H. (2019). Why, when, and how to give surfactant. Pediatric Research, 86(1), 15–16. https://doi.org/10.1038/s41390-019-0372-1Ng, E. H., & Shah, V. (2021). Guidelines for surfactant replacement therapy in neonates. Paediatrics & child health, 26(1), 35–49. https://doi.org/10.1093/pch/pxaa116Razak, A. (2022). Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. JAMA: Journal of the American Medical Association, 327(16), 1613. https://doi.org/10.1001/jama.2022.2923For definitions of the terms we used, check out the full episode page at TTN vs RDS

Dr. Watterberg is a Professor Emerita of Pediatrics in the Division of Neonatology at the University of New Mexico Health Sciences Center.  She served as Chief of the Division from 2006 – 2011, and Director of the UNM Signature Program in Child Health Research from 2011 – 2016.   Dr. Watterberg has over 30 years' experience conducting studies exploring newborn adrenal function, its relationship to inflammation and BPD, and long-term outcomes after preterm birth.   She is the New Mexico Principal Investigator for the NICHD Neonatal Research Network (NRN, 2006-2023), which has multiple ongoing observational and interventional studies.  She also was awarded a grant from NIH to study adrenal function at age six in a cohort of NRN children born extremely preterm (R01HL117764; 2013 – 2019). She has mentored fellows, faculty and other learners in research and academic advancement.  Dr. Watterberg has served on NIH peer review panels and is a member of the Society for Pediatric Research and the American Pediatric Society.   She has been an AAP member throughout her career, and has served on the Committee on Fetus and Newborn (COFN) as a member from 2006 – 2012, and as chair (2013 – 2017). Find out more about Kristi and this episode at: www.nicupodcast.com______________________________________________________________________________________As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. enjoy!This podcast is proudly sponsored by Chiesi.

Joyce Lee MD is a Physician, Designer, Researcher, and the Robert P. Kelch, MD, Research Professor of Pediatrics at the University of Michigan. She is a Diabetologist (Pediatric Endocrinologist focused on Diabetes) and a clinical/health outcomes researcher with work focusing on the creation of learning health systems. She serves as Ambulatory Clinical Chief of Pediatric Medical Specialties, Associate Chief Medical Information Officer for Pediatric Research, and Associate Chair of Health Metrics and Learning Health Systems for the Department of Pediatrics.  Joyce on Twitter Kristy M. Shine, MD, PhD is an Assistant Professor of Emergency Medicine at Thomas Jefferson University and Director of Scholarly Inquiry, Design, at the Sidney Kimmel Medical College. In addition to her role as attending physician and core faculty for the residency, Dr. Shine has worked in the medical device industry and holds graduate degrees in mechanical engineering and medical engineering/medical physics.  She believes that training doctors to be compassionate innovators will change the future of medicine. Kristy on Twitter

Dr. Fort is the chair for the research council at the Maternal, Fetal, and Neonatal institute at Johns Hopkins All Children's Hospital. He is a board-certified pediatrician and neonatologist with a research focus in respiratory medicine in preterm infants. He attended undergraduate education at the University of North Carolina and continued his medical training with the School of Medicine at the University of North Carolina, pediatrics residency at Duke University Medical Center, and Neonatal-Perinatal fellowship at the University of Alabama in Birmingham. He has successfully presented research studies at the National Child Health and Human Development (NICHD), and has been and is currently involved in a multitude of multicenter, regional and national clinical trials. He has been the recipient of teaching awards as well as two prestigious awards from the Society of Pediatric Research for his study in vitamin D use in extremely preterm infants. He is recognized nationally and internationally as an expert in respiratory care with minimally invasive methods of surfactant administration, a drug that is needed for preterm infants to breath. He is constantly striving to improve the care of newborn, preterm infants through research and Best Practice in clinical care. Find out more about Prem and this episode at: www.nicupodcast.com________________________________________________________________________________________As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. enjoy!This podcast is proudly sponsored by Chiesi.

Dr. Jill L. Maron is a Professor of Pediatrics, Obstetrics, and Gynecology at Tufts University School of Medicine. She is the Executive Director of the Mother Infant Research Institute at Tufts Medical Center and the Vice-Chair of Pediatric Research at Tufts Children's Hospital. She also serves as the Co-Editor-in-Chief for Clinical Therapeutics. For over 15 years, Dr. Maron's research has focused on developing and integrating novel salivary and genetic diagnostic platforms into neonatal and maternal care. Dr. Maron is internationally recognized for her contributions to the development of neonatal salivary diagnostic platforms. She has received multiple awards for her research, given a TEDx talk on the subject of neonatal diagnostics, and has published extensively in the field. Dr. Maron received her undergraduate degree from Harvard University, and she holds an MD and MPH degree from Tulane University. In this episode… When babies are sick, they can't describe their symptoms, so you need another way of assessing what's wrong. Drawing blood is one option for diagnosing problems, but sticking newborns with needles over and over can be traumatic — and might have long-lasting adverse effects. A less invasive method of identifying issues is through saliva — but what can spit actually tell us about the health of a baby? Dr. Jill L. Maron, Executive Director of the Mother Infant Research Institute at Tufts Medical Center, claims that a small drop of spit can tell us quite a bit. She's been at the forefront of salivary diagnostics in neonatal care for the past 15 years and is currently researching to see if saliva can be used to diagnose infections. According to Dr. Maron, biofluid will remain a part of diagnostics well into the future as she and other saliva investigators continue to advance the field. In this episode of the Measure Success Podcast, Carl J. Cox talks with Dr. Jill L. Maron, Executive Director of the Mother Infant Research Institute at Tufts Medical Center, about using salivary diagnostics in neonatal care. Dr. Maron explains how salivary diagnostics have evolved over the last 15 years, why she became interested in studying saliva, and where her current research is focused. Plus, Dr. Maron and Carl J. Cox discuss sports, books, and their grandmothers. Stay tuned!

In the fourth episode of ASPHOcast, guest Dr. Mike Engel discusses his perspectives on division and department culture as it relates to clinician wellness, particularly as it relates to personal and professional integration. Dr. Engel is currently Professor of Pediatrics and Division Chief in Pediatric Hematology/Oncology at the University of Virginia School of Medicine. He also serves as Vice Chair of Pediatric Research at UVA.

FDA 批准MAPK激酶抑制剂治疗手术无法切除的1型神经纤维瘤BMJ 哮喘发作与空气污染和母亲孕期吸烟有关Nature Metabolism 母亲运动带来的后代的健康获益是通过母乳中的3′-唾液酸乳糖介导的司美替尼（selumetinib）神经纤维瘤是常染色体显性遗传病，分1、2和3型。1型神经纤维瘤最常见，标志性特征是多发的牛奶咖啡斑和相关皮肤神经纤维瘤。没有针对性的总体的治疗，只能对症治疗。50%的1型神经纤维瘤患者合并丛状神经纤维瘤，丛状神经纤维瘤是一种组织学上良性的周围神经鞘肿瘤，常累及多个神经束，造成毁容、运动功能障碍、疼痛、甚至脊髓受压。司美替尼是一种MAPK激酶的抑制剂，在2020年4月，FDA批准了司美替尼用于治疗1型神经纤维瘤。《司美替尼治疗不能手术的丛状神经纤维瘤患儿》New England Journal of Medicine，2020年4月 (1)这项开放标签的2期试验，旨在确定丛状神经纤维瘤患儿服用司美替尼后的临床益处和安全性。50名、平均年龄10.2岁的、不能手术的丛状神经纤维瘤的1型神经纤维瘤病患儿入组，随机接受了司美替尼和安慰剂治疗。最常见的神经纤维瘤相关症状包括毁容（44人）、运动功能障碍（33人）和疼痛（26人）。治疗后70%达到了部分缓解，56%≥1年的持久缓解。1年后，肿瘤疼痛评分平均降低了2分，疼痛对日常功能、总体健康相关生活质量、力量和关节活动范围等多项功能结局也观察到了有临床意义的改善。其中5人因副作用停药；6人疾病发展。最常见的毒性作用为恶心、呕吐或腹泻、无症状的肌酸磷酸激酶水平升高、痤疮样皮疹及甲沟炎。结论：对于手术无法切除的丛状神经纤维瘤患儿，司美替尼产生了持久的缩小肿瘤作用。儿童哮喘哮喘（asthma）是一种异质性疾病，特点是慢性气道炎症。12岁以下儿童哮喘是最常见的儿童期慢性疾病，约80%的患儿在5岁以前出现症状，咳嗽、哮鸣、呼吸急促、胸闷胸痛是常见的症状。最常见的诱发因素包括病毒性上呼吸道感染（合胞病毒、流感病毒、鼻病毒）、运动、天气、二手烟和变应原（如尘螨、宠物毛发、花粉、霉菌）。《病例队列研究：空气污染和家庭相关因素与儿童哮喘发作和持续性喘息的关系》BMJ，2020年8月(2)研究目的探讨儿童哮喘和持续性喘息发病的危险因素（空气污染和家庭相关因素）。这项全国病例对照研究中随访了1-15岁儿童儿童哮喘发病率升高，与父母患有哮喘（风险比 2.29）、母亲在怀孕期间吸烟（风险比 1.20）相关。儿童哮喘发病率低，与父母受教育程度高（风险比0.72）和父母收入高（风险比 0.85）相关。空气污染物PM2.5和PM10与哮喘的风险增加和持续喘息相关。结论：暴露于空气污染中的儿童更容易患哮喘和持续性喘息，哮喘与父母哮喘病史、父母教育程度和母亲在怀孕期间吸烟有关。《观察性研究：母亲在怀孕期间吸烟影响子女成年后哮喘发作》European Respiratory Journal 2020年7月 (3)研究的目的是确定产前哮喘和成人哮喘发病之间的关系。研究纳入5200名、1966年芬兰北部出生的、31岁前未诊断为哮喘的人群。研究发现孕妇妊娠最后3个月吸烟，其后代31岁至46岁之间哮喘累积发病率（男性为5.1%，女性为8.8%），尤其是与无哮喘病史（风险比9.63）或咳嗽喘息病史（风险比3.21）的后代中有显著相关性。同时在妊娠期吸烟与31岁时子代的用力呼气量（FEV1）/用力肺活量（FVC）比率之间有发现了显著的相关性，在在RUNX1单倍型rs11702779-AA的后代中成年期患哮喘的风险比为5.53。结论：怀孕期间吸烟与后代成年后哮喘累积发病率有关。《观察性研究：空气污染和从出生到成年的哮喘发展》European Respiratory Journal 2020年7月 (4)空气污染对青春期至成年期哮喘发展的影响尚不清楚，研究纳入了3687个参与者，评估空气污染和哮喘发生的年龄的相关关系。研究20岁之前哮喘的发病率，与出生地空气污染物的比例增加相关（接触PM10的风险比为1.09，接触NO2的风险比为1.20）。对近期家庭居住地的空气污染进行分析后，得到了类似的结果。结论：早年暴露在空气污染中，特别是来自机动交通的污染，与儿童、青春期到成年早期罹患哮喘的风险增加有关。《哮喘患儿卧室颗粒物过滤与气道病理生理变化的关系》JAMA Pediatrics，2020年8月 (5)细颗粒物PM2.5是一种普遍存在的空气污染物，可沉积在小气道中，对哮喘起着至关重要的作用。来自杜克大学与北京上海的研究人员合作，研究PM2.5过滤装置的使用是否能改善哮喘患儿的小气道生理学和呼吸系统炎症。研究人员在患儿的卧室里随机安装了真实的过滤设备和假的过滤设备，试验前有2周的洗脱期，研究是在臭氧含量低的季节在中国上海的郊区进行的。研究纳入轻中度哮喘的、共43个、5-13岁的儿童参加了研究。室外PM2.5浓度中度升高（28.6-69.8μg/m3)；经过滤的卧室PM2.5浓度比不经过滤降低63.4%。过滤的卧室空气能显著改善气道力学，总气道阻力下降24.4%，减少小气道阻力43.5%，呼气流量峰值也显著改善。这些改善与卧室PM2.5的减少显著相关。总体的小气道功能改善均没有统计学意义，但在不伴有嗜酸性气道炎症的参与者中改善显著（13.2%）。结论：室内PM2.5过滤可以通过改善气道力学和功能，减少炎症，改善哮喘患者肺部的气体流动。《VDKA研究：补充维生素D3对低维生素D和哮喘患儿哮喘加重的影响》JAMA，2020年8月 (6)研究的目的探讨维生素D3的补充是否能改善儿童哮喘和低维生素D水平严重恶化的时间。这项随机、双盲、安慰剂对照临床试验，纳入6-16岁的、哮喘严重发作高危儿童共192人，平均年龄9.8岁，女孩40%维生素D3组的37.5%和安慰剂组的34.4%出现≥1次严重恶化。补充维生素D3并没有显著改善哮喘严重恶化的时间，没有显著改善病毒诱导哮喘严重加重的时间，没有显著改善糖皮质激素剂量减量的患者比例，也没有显著减少糖皮质激素的累积剂量。两组严重不良事件相似。结论：该研究不支持在持续性哮喘和低维生素D水平的儿童维生素D3来预防哮喘加重。《前瞻性队列研究：抗生素的使用减少，影响肠道菌群和儿童哮喘发病率》Lancet Respiratory Medicine，2020年7月 (7)在欧洲和北美的一些地区，儿童哮喘的发病率正在下降；有研究提示婴儿期使用抗生素与哮喘风险增加有关。该研究的目的是验证哮喘发病率的降低是否与抗生素处方减少有关，并验证这种变化是由肠道菌群变化介导的。本研究包括基于人群和前瞻性队列分析，使用加拿大不列颠哥伦比亚省（人口400万·700万）每年抗生素处方率和哮喘诊断率的管理数据进行人群分析。2000 - 2014年，1-4岁儿童的哮喘发病率从27·3‰ 下降到20·2‰，降幅26·0%。发病率的降低与

Bri Christophers (she) is an aspiring physician-scientist interested in bringing social justice to the lab bench and hospital bedside. Born and raised in Miami, Bri found herself moving to New Jersey to attend Princeton University, where she fell in love with developmental biology while staring at fish hearts down a microscope in the lab of Rebecca Burdine, PhD. Much of her advocacy work as an undergraduate focused on amplifying the voices of Latinx, BIPOC*, and first-generation/low-income students through organizations like Princeton Latinos y Amigos, the Latinx Collective and initiatives like Project Welcome Mat: A Guide for First-Generation Students. Her work was recognized with the Frederick Douglass Service Award given during graduation ceremonies, the Spirit of Princeton Award, and the Santos-Dumont Award for Innovation. She continued her journey in developmental biology by working in the lab of Robert Heuckeroth, MD, PhD at the Children's Hospital of Philadelphia, moving from the heart to the enteric nervous system. Now as an MD-PhD student at Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, she is pursuing graduate training with Mary Baylies, PhD, studying muscle development. Briana has continued to bring together her passion for scientific discovery and advocacy, serving as diversity representative on the Weill Cornell Medical Student Executive Committee, co-running the Association of Diverse Physician-Scientists in Training (ADePT), and developing the Mini Lessons by Medical Scientists video series aimed at introducing children and adolescents to physician-scientists. More recently, Bri has turned to writing as a way of communicating science and advancing social causes. Her works have been published in Academic Medicine, the Journal of Clinical Investigation, The Lancet Global Health, Pediatric Research, Scientific American, and in-Training magazine. She co-authored and was lead editor of “The Free Guide to Medical School Admissions,” an e-book in its second-edition available at tiny.cc/MedAppGuide. You can follow her reflections on being a Latina growing into a pediatrician-scientist on Twitter, where she is also the co-leader of @LatinasInMed and @MedStudentChat.

What are fatty acid oxidation disorders, and why are they related to mitochondrial disorders? Additional areas of discussion include: Do patients with mitochondrial defects also have the potential to have fatty acid oxidation defects? How do disorders of metabolism such as FAOD and mitochondrial disease impact the body’s ability to grow, develop and function? What is the current focus in research for understanding and treating FAODs? Special appreciation to Ultragenyx Pharmaceutical for support of this presentation. About the Speaker Dr. Jerry Vockley, University of Pittsburgh Cleveland Family Professor of Pediatric Research and Professor of Human Genetics at the Children’s Hospital of Pittsburgh of UPMC. Dr. Vockley is the Chief of Medical Genetics and Director of the Center for Rare Disease Therapy. To view the accompanying slides, click here.

The stem cells in bone marrow, so important to fighting disease, are themselves vulnerable to infections that can deplete them over time. Those findings, along with research into new ways to protect stem cells, are part of the work at the Baylor College of Medicine, where Dr. Katherine King is an associate professor of pediatrics. Her research garnered one of this year's Presidential Early Career Awards for Scientists and Engineers from the White House Office of Science and Technology Policy. King talked about her work with Federal News Network's Jared Serbu on Federal Drive with Tom Temin.